• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1.逆转录病毒插入激活 Janus 激酶 1 诱导的成熟 T 细胞淋巴肿瘤发生。
Mol Ther. 2013 Jun;21(6):1160-8. doi: 10.1038/mt.2013.67. Epub 2013 Apr 23.
2
Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes.逆转录病毒插入突变可能导致成熟 T 淋巴细胞永生化。
Mol Med. 2011;17(11-12):1223-32. doi: 10.2119/molmed.2010.00193. Epub 2011 Jul 27.
3
T lymphocytes are not immune.T淋巴细胞没有免疫能力。
Mol Ther. 2013 Jun;21(6):1114-5. doi: 10.1038/mt.2013.102.
4
Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways.Janus酪氨酸激酶(Jak)1的共激活正向调节乳腺癌中催乳素-Jak2信号传导:募集细胞外信号调节激酶(ERK)和信号转导及转录激活因子(Stat)3,并增强Akt和Stat5a/b信号通路。
Mol Endocrinol. 2007 Sep;21(9):2218-32. doi: 10.1210/me.2007-0173. Epub 2007 Jun 5.
5
Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells.孕激素通过一种依赖于Jak和Src的机制诱导乳腺癌细胞中信号转导子和转录激活子3(Stat3)的转录激活。
Mol Cell Biol. 2005 Jun;25(12):4826-40. doi: 10.1128/MCB.25.12.4826-4840.2005.
6
Phosphorylation of Janus kinase 1 (JAK1) by AMP-activated protein kinase (AMPK) links energy sensing to anti-inflammatory signaling.AMP激活的蛋白激酶(AMPK)对Janus激酶1(JAK1)的磷酸化作用将能量感知与抗炎信号传导联系起来。
Sci Signal. 2016 Nov 8;9(453):ra109. doi: 10.1126/scisignal.aaf8566.
7
Investigation of the mutations in the genes involved in Janus kinase/signal transducer and activator of transcription pathway in canine large cell gastrointestinal lymphoma.犬大细胞胃肠道淋巴瘤中与Janus激酶/信号转导及转录激活因子通路相关基因的突变研究
J Vet Med Sci. 2024 Oct 1;86(10):1052-1055. doi: 10.1292/jvms.24-0096. Epub 2024 Aug 13.
8
Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy.逆转录病毒载体的整合会使接受基因治疗的腺苷脱氨酶严重联合免疫缺陷(ADA - SCID)患者的T细胞转录活性发生微小变化。
Blood. 2009 Oct 22;114(17):3546-56. doi: 10.1182/blood-2009-02-202085. Epub 2009 Aug 3.
9
JAK kinases overexpression promotes in vitro cell transformation.JAK激酶的过表达促进体外细胞转化。
Oncogene. 2008 Mar 6;27(11):1511-9. doi: 10.1038/sj.onc.1210800. Epub 2007 Sep 17.
10
Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity.在v-Src转化的成纤维细胞中,Stat3的激活需要Jak1激酶活性的协同作用。
J Biol Chem. 2000 Aug 11;275(32):24935-44. doi: 10.1074/jbc.M002383200.

引用本文的文献

1
Current landscape of vector safety and genotoxicity after hematopoietic stem or immune cell gene therapy.造血干细胞或免疫细胞基因治疗后载体安全性和基因毒性的当前状况。
Leukemia. 2025 Apr 8. doi: 10.1038/s41375-025-02585-8.
2
Clinical development of allogeneic chimeric antigen receptor αβ-T cells.同种异体嵌合抗原受体αβ-T细胞的临床开发
Mol Ther. 2025 Jun 4;33(6):2426-2440. doi: 10.1016/j.ymthe.2025.03.040. Epub 2025 Mar 27.
3
Models for T-large granular lymphocytic leukemia: how to mimic the cellular interplays in malignant autoimmunity.T 大颗粒淋巴细胞白血病模型:如何模拟恶性自身免疫中的细胞相互作用。
Leukemia. 2025 Apr;39(4):792-804. doi: 10.1038/s41375-025-02553-2. Epub 2025 Mar 7.
4
The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?嵌合抗原受体 T 细胞疗法后继发性恶性肿瘤的现状:如何预防恶性肿瘤?
Int J Mol Sci. 2024 Sep 1;25(17):9518. doi: 10.3390/ijms25179518.
5
Current progress in CAR-based therapy for kidney disease.基于嵌合抗原受体(CAR)的肾脏疾病治疗的最新进展。
Front Immunol. 2024 Aug 20;15:1408718. doi: 10.3389/fimmu.2024.1408718. eCollection 2024.
6
CAR T-cell Resistance to Oncogenic Transformation.嵌合抗原受体 T 细胞对致癌转化的抵抗。
Blood Cancer Discov. 2024 Jul 1;5(4):229-233. doi: 10.1158/2643-3230.BCD-23-0273.
7
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.商业 CAR T 细胞治疗后 T 细胞淋巴瘤和继发原发性恶性肿瘤风险。
Nat Med. 2024 Apr;30(4):984-989. doi: 10.1038/s41591-024-02826-w. Epub 2024 Jan 24.
8
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy.嵌合抗原受体T细胞(CAR-T)疗法后出现继发性恶性肿瘤报告后的未解问题。
Nat Med. 2024 Feb;30(2):338-341. doi: 10.1038/s41591-023-02767-w.
9
Tyrosine kinases in nodal peripheral T-cell lymphomas.淋巴结外周T细胞淋巴瘤中的酪氨酸激酶
Front Oncol. 2023 Feb 8;13:1099943. doi: 10.3389/fonc.2023.1099943. eCollection 2023.
10
Two cases of T cell lymphoma following Piggybac-mediated CAR T cell therapy.两例经Piggybac介导的嵌合抗原受体T细胞(CAR T)疗法后发生的T细胞淋巴瘤病例。
Mol Ther. 2021 Sep 1;29(9):2631-2633. doi: 10.1016/j.ymthe.2021.08.013. Epub 2021 Aug 24.

本文引用的文献

1
T-cell receptor diversity prevents T-cell lymphoma development.T 细胞受体多样性可预防 T 细胞淋巴瘤发生。
Leukemia. 2012 Dec;26(12):2499-507. doi: 10.1038/leu.2012.142. Epub 2012 May 30.
2
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells.逆转录病毒修饰的嵌合抗原受体 T 细胞的十年安全性和功能。
Sci Transl Med. 2012 May 2;4(132):132ra53. doi: 10.1126/scitranslmed.3003761.
3
Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets.解析肝脾 T 细胞淋巴瘤的分子特征揭示潜在的新治疗靶点。
Blood. 2012 Jun 14;119(24):5795-806. doi: 10.1182/blood-2011-12-396150. Epub 2012 Apr 17.
4
Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy.开发具有改进安全性特征的新型高效 SIN 载体,用于基于 Wiskott-Aldrich 综合征干细胞的基因治疗。
Mol Pharm. 2011 Oct 3;8(5):1525-37. doi: 10.1021/mp200132u. Epub 2011 Aug 31.
5
Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes.逆转录病毒插入突变可能导致成熟 T 淋巴细胞永生化。
Mol Med. 2011;17(11-12):1223-32. doi: 10.2119/molmed.2010.00193. Epub 2011 Jul 27.
6
Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic γδ T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro.自然杀伤细胞淋巴瘤与一组非肝脾 γδ T 细胞淋巴瘤具有惊人相似的分子特征,并且对新型极光激酶 A 抑制剂在体外具有高度敏感性。
Leukemia. 2011 Feb;25(2):348-58. doi: 10.1038/leu.2010.255. Epub 2010 Nov 5.
7
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.选择性 JAK1/2 抑制剂 INCB018424 的临床前特征:治疗骨髓增生性肿瘤的治疗意义。
Blood. 2010 Apr 15;115(15):3109-17. doi: 10.1182/blood-2009-04-214957. Epub 2010 Feb 3.
8
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease.基因治疗慢性肉芽肿病后 EVI1 激活导致基因组不稳定和 7 号单体性骨髓增生异常。
Nat Med. 2010 Feb;16(2):198-204. doi: 10.1038/nm.2088. Epub 2010 Jan 24.
9
Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.改善外周 T 细胞淋巴瘤诊断和血管免疫母细胞性 T 细胞淋巴瘤预后的分子标志物。
Blood. 2010 Feb 4;115(5):1026-36. doi: 10.1182/blood-2009-06-227579. Epub 2009 Nov 18.
10
Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.间变性大细胞淋巴瘤中分离出的肿瘤细胞的基因表达谱分析:对其细胞起源、发病机制及与霍奇金淋巴瘤关系的见解
Leukemia. 2009 Nov;23(11):2129-38. doi: 10.1038/leu.2009.161. Epub 2009 Aug 6.

逆转录病毒插入激活 Janus 激酶 1 诱导的成熟 T 细胞淋巴肿瘤发生。

Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1.

机构信息

Senckenberg Institute of Pathology, Goethe-University Hospital, Frankfurt am Main, Germany.

出版信息

Mol Ther. 2013 Jun;21(6):1160-8. doi: 10.1038/mt.2013.67. Epub 2013 Apr 23.

DOI:10.1038/mt.2013.67
PMID:23609016
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3677306/
Abstract

Retroviral vectors (RVs) are powerful tools in clinical gene therapy. However, stable genomic integration of RVs can be oncogenic, as reported in several animal models and in clinical trials. Previously, we observed that T-cell receptor (TCR) polyclonal mature T cells are resistant to transformation after gammaretroviral transfer of (proto-)oncogenes, whereas TCR-oligoclonal T cells were transformable in the same setting. Here, we describe the induction of a mature T-cell lymphoma (MTCL) in TCR-oligoclonal OT-I transgenic T cells, transduced with an enhanced green fluorescent protein (EGFP)-encoding gammaretroviral vector. The tumor cells were of a mature T-cell phenotype and serially transplantable. Integration site analysis revealed a proviral hit in Janus kinase 1 (Jak1), which resulted in Jak1 overexpression and Jak/STAT-pathway activation, particularly via signal transducer and activator of transcription 3 (STAT3). Specific inhibition of Jak1 markedly delayed tumor growth. A systematic meta-analysis of available gene expression data on human mature T-cell lymphomas/leukemias confirmed the relevance of Jak/STAT overexpression in sporadic human T-cell tumorigenesis. To our knowledge, this is the first study to describe RV-associated insertional mutagenesis in mature T cells.

摘要

逆转录病毒载体 (RVs) 是临床基因治疗中的有力工具。然而,正如在几个动物模型和临床试验中所报道的那样,RV 的稳定基因组整合可能具有致癌性。先前,我们观察到,T 细胞受体 (TCR) 多克隆成熟 T 细胞在 γ 逆转录病毒转导 (原) 癌基因后不易发生转化,而 TCR 寡克隆 T 细胞在相同条件下可发生转化。在这里,我们描述了 TCR-寡克隆 OT-I 转基因 T 细胞在转导增强型绿色荧光蛋白 (EGFP) 编码 γ 逆转录病毒载体后诱导成熟 T 细胞淋巴瘤 (MTCL)。肿瘤细胞具有成熟 T 细胞表型,并可连续移植。整合位点分析显示,Janus 激酶 1 (Jak1) 中存在前病毒命中,导致 Jak1 过表达和 Jak/STAT 通路激活,特别是通过信号转导和转录激活因子 3 (STAT3)。Jak1 的特异性抑制显著延迟了肿瘤生长。对人类成熟 T 细胞淋巴瘤/白血病的现有基因表达数据进行的系统荟萃分析证实了 Jak/STAT 过表达在散发性人类 T 细胞肿瘤发生中的相关性。据我们所知,这是第一项描述成熟 T 细胞中与 RV 相关的插入突变的研究。